Fig. 6.

ARB affects SLC7A11 to inhibit ferroptosis. (A) CCK8 detects the effect of 0.1–100 μM Erastin treated cells for 24 h on cell viability (n = 3 per group). (B) CCK8 detects the effect of 10 μM Erastin treated cells for 24 h on intracellular TG content (n = 3 per group). (C–E) Fe, Fe²⁺, and Fe²⁺ to Fe³⁺ ratio (n = 3–4 per group). (F–G) Calcein staining (n = 3–4 per group). (H) Effect of 1–100 nM Fer-1 treated cells for 24 h on cell viability (n = 3 per group). (I) Effect of 10 nM Fer-1 treated cells for 24 h on intracellular TG content (n = 3–4 per group). (J–K) Calcein staining (n = 3–4 per group). (L) Effect of siSLC7A11 on intracellular TG content (n = 3–4 per group). (M–O) Effect of siSLC7A11 on intracellular ROS and GSH (n = 3–4 per group). (P–R) Fe, Fe²⁺, and Fe²⁺ to Fe³⁺ ratio (n = 4 per group). (S–T) Calcein staining (n = 3–4 per group). (U) Effect of SLC7A11 overexpression on intracellular TG content (n = 3 per group). (V–X) Effect of SLC7A11 overexpression on intracellular ROS and GSH (n = 3–4 per group). (Y) Fe, Fe²⁺, and Fe²⁺ to Fe³⁺ ratio (n = 4 per group). (Z) Calcein staining (n = 3–4 per group). Data are mean ± SEM, n ≥ 3; One-way ANOVA was used to compare the means of three groups, ∗P < 0.05; ∗∗P < 0.01.